title: Facilitated intranasal induction of mucosal and systemic immunity to mutans streptococcal glucosyltransferase peptide vaccines.
abstract: Synthetic peptide vaccines which are derived from functional domains of Streptococcus mutans glucosyltransferases (GTF) have been shown to induce protective immunity in Sprague-Dawley rats after subcutaneous injection in the salivary gland region. Since mucosal induction of salivary immunity would be preferable in humans, we explored methods to induce mucosal antibody in the rat to the GTF peptide vaccines HDS and HDS-GLU after intranasal administration. Several methods of facilitation of the immune response were studied: the incorporation of peptides in bioadhesive poly(D,L-lactide-coglycolide) (PLGA) microparticles, the use of monoepitopic (HDS) or diepitopic (HDS-GLU) peptide constructs, or the use of mucosal adjuvants. Salivary immunoglobulin A (IgA) responses were not detected after intranasal administration of diepitopic HDS-GLU peptide constructs in alum or after incorporation into PLGA microparticles. However, significant primary and secondary salivary IgA and serum IgG antibody responses to HDS were induced in all rats when cholera holotoxin (CT) or a detoxified mutant Escherichia coli heat-labile enterotoxin (R192G LT) were intranasally administered with HDS peptide constructs in PLGA. Coadministration of LT with HDS resulted in predominantly IgG2a responses in the serum, while coadministration with CT resulted in significant IgG1 and IgG2a responses to HDS. Serum IgG antibody, which was induced to the HDS peptide construct by coadministration with these adjuvants, also bound intact mutans streptococcal GTF in an enzyme-linked immunosorbent assay and inhibited its enzymatic activity. Thus, immune responses which are potentially protective for dental caries can be induced to peptide-based GTF vaccines after mucosal administration if combined with the CT or LT R192G mucosal adjuvant.
authors.affiliation: Department of Immunology, The Forsyth Institute, Boston, Massachusetts 02115, USA. dsmith@forsyth.org
authors.forename: D J
authors.initials: DJ
authors.lastname: Smith
authors.forename: W F
authors.initials: WF
authors.lastname: King
authors.forename: L A
authors.initials: LA
authors.lastname: Barnes
authors.forename: D
authors.initials: D
authors.lastname: Trantolo
authors.forename: D L
authors.initials: DL
authors.lastname: Wise
authors.forename: M A
authors.initials: MA
authors.lastname: Taubman
mesh_terms: D000276:Adjuvants, Immunologic; D000281:Administration, Intranasal; D000595:Amino Acid Sequence; D000818:Animals; D001427:Bacterial Toxins / Q000276:immunology*; D002772:Cholera Toxin / Q000276:immunology*; D004768:Enterotoxins / Q000276:immunology*; D018985:Epitopes, B-Lymphocyte / Q000276:immunology; D029968:Escherichia coli Proteins; D005260:Female; D005964:Glucosyltransferases / Q000276:immunology*; D018928:Immunity, Mucosal / Q000276:immunology; D007117:Immunization, Secondary; D007070:Immunoglobulin A / Q000378:metabolism; D008297:Male; D008969:Molecular Sequence Data; D010455:Peptides / Q000276:immunology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012463:Saliva / Q000276:immunology; D022541:Streptococcal Vaccines / Q000276:immunology*; D013295:Streptococcus mutans / Q000201:enzymology* / Q000276:immunology; D014614:Vaccines, Synthetic / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D001427:Bacterial Toxins; D004768:Enterotoxins; D018985:Epitopes, B-Lymphocyte; D029968:Escherichia coli Proteins; D007070:Immunoglobulin A; D010455:Peptides; D022541:Streptococcal Vaccines; D014614:Vaccines, Synthetic; D002772:Cholera Toxin; C027538:heat-labile enterotoxin, E coli; D005964:Glucosyltransferases